


Delandistrogene Moxeparvovec in Duchenne Muscular Dystrophy: Functional and Safety Outcomes up to 3 Years Post-Infusion in the EMBARK Study

Jerry R. Mendell,¹ Francesco Muntoni,² Craig M. McDonald,³ Eugenio M. Mercuri,⁴ Emma Ciafaloni,⁵ Hirofumi Komaki,⁶ Carmen Leon-Astudillo,⁷ Andrés Nascimento,⁸ Crystal Proud,⁹ Ulrike Schara-Schmidt,¹⁰ Aravindhan Veerapandiyan,¹¹ Craig M. Zaidman,¹² Matthew Furgerson,¹ Jim Jin,¹ Mark Vivien,¹ Damon R. Asher,¹ Alexander P. Murphy,¹³ Carol Reid,^{13*} Marianne Gerber,¹⁴ Carmen O. Torre,¹³ Marianna Manfrini,¹⁴ Louise R. Rodino-Klapac¹

¹Sarepta Therapeutics, Inc., Cambridge, MA, USA; ²Dubowitz Neuromuscular Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health and Institute of Neurology, University College London and Great Ormond Street Hospital Trust, London, UK; ³UC Davis Health, Sacramento, CA, USA; ⁴Pediatric Neurology Institute, Catholic University and Nemo Pediatrico, Fondazione Policlinico Gemelli IRCCS, Rome, Italy; ⁵University of Rochester Medical Center, Rochester, NY, USA; ⁶Translational Medical Center, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan; ⁷Department of Pediatrics, University of Florida, Gainesville, FL, USA; ⁸Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, Fundacion Sant Joan de Déu, CIBERER – ISC III, Barcelona, Spain; ⁹Children’s Hospital of the King’s Daughters, Norfolk, VA, USA; ¹⁰Department of Pediatric Neurology, Center for Neuromuscular Disorders in Children and Adolescents, University Clinic Essen, University of Duisburg-Essen, Essen, Germany; ¹¹Department of Pediatrics, Division of Neurology, University of Arkansas for Medical Sciences, Arkansas Children’s Hospital, Little Rock, AR, USA; ¹²Department of Neurology, Washington University in St Louis, St Louis, MO, USA; ¹³Roche Products Ltd, Welwyn Garden City, UK; ¹⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland. *Previously an employee of Roche Products Ltd.

Supplementary information



Supplementary Table 1 *Key inclusion criteria*¹

Key inclusion criteria	
Ambulatory males aged ≥4 to <8 years at randomization	TTR <5 seconds at screening
Confirmed DMD diagnosis (<i>DMD</i> mutation fully contained within exons 18–79 [inclusive], excluding mutations fully contained within exon 45 [inclusive])	On a stable daily dose of oral corticosteroids for ≥12 weeks before screening
Ability to cooperate with motor assessment testing	rAAVrh74 total binding antibody titers <1:400
NSAA total score >16 and <29 points at screening	